- Home
- YCBD vs APRE Comparison
YCBD vs APRE Comparison
Compare YCBD & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- APRE
- Stock Information
- Founded
- YCBD 2015
- APRE 2006
- Country
- YCBD United States
- APRE United States
- Employees
- YCBD N/A
- APRE N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YCBD Health Care
- APRE Health Care
- Exchange
- YCBD Nasdaq
- APRE Nasdaq
- Market Cap
- YCBD 7.8M
- APRE 8.3M
- IPO Year
- YCBD N/A
- APRE 2019
- Fundamental
- Price
- YCBD $0.88
- APRE $1.45
- Analyst Decision
- YCBD Strong Buy
- APRE Strong Buy
- Analyst Count
- YCBD 1
- APRE 1
- Target Price
- YCBD $2.00
- APRE $20.00
- AVG Volume (30 Days)
- YCBD 608.2K
- APRE 142.2K
- Earning Date
- YCBD 12-17-2025
- APRE 11-07-2025
- Dividend Yield
- YCBD N/A
- APRE N/A
- EPS Growth
- YCBD N/A
- APRE N/A
- EPS
- YCBD N/A
- APRE N/A
- Revenue
- YCBD $19,026,064.00
- APRE $841,012.00
- Revenue This Year
- YCBD $0.37
- APRE N/A
- Revenue Next Year
- YCBD $4.95
- APRE N/A
- P/E Ratio
- YCBD N/A
- APRE N/A
- Revenue Growth
- YCBD N/A
- APRE N/A
- 52 Week Low
- YCBD $0.59
- APRE $1.31
- 52 Week High
- YCBD $6.54
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- YCBD 40.93
- APRE 46.64
- Support Level
- YCBD $0.94
- APRE $1.31
- Resistance Level
- YCBD $1.09
- APRE $1.49
- Average True Range (ATR)
- YCBD 0.13
- APRE 0.10
- MACD
- YCBD -0.05
- APRE -0.01
- Stochastic Oscillator
- YCBD 5.27
- APRE 36.84
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.